Grant: Doctoral Award - Doctoral Foreign Study Award (DFSA)
Direct Payment
$105,000.00
Endogenous retroelements as novel immune escape mechanisms in human cancers
FY 2018-19
Summary
Immunotherapy has drastically changed the landscape of cancer treatment. By retargeting the body's own immune system towards a tumour, immunotherapy has proved effective where more traditional therapies have failed. However, tumours have developed sophisticated mechanisms to evade the anti-tumour immune response, thus rendering such immunotherapies ineffective. The advent of next-generation sequencing technologies has highlighted the importance of the non-coding genome in health and disease. A significant proportion of these non-coding genes comprise endogenous retroviruses (ERVs), remnants of ancient viral infections that have since become a part of human DNA. Given their viral origins, these genes have retained their capacity to modulate immune responses. As ERVs and other retroelements are globally deregulated in cancer cells, we propose that they may promote the immune evasive capacity of tumours. Our preliminary analysis of gene expression patterns from 964 cancer patients comprising 31 tumour types has uncovered a novel subset of immune genes that may be regulated by ERVs and other retroelements. My preliminary findings show a novel mechanism by which a retroelement drives expression of alternative soluble form of PD-L1, a molecule that inhibits antitumour immune responses and is thus a key immunotherapeutic target. We propose that this retroelement-derived PD-L1 may affect patient response to immunotherapy, which we will test using in vitro and in vivo models as well as screening patient samples. We aim to uncover diverse mechanisms by which ERVs can contribute to resistance to immunotherapy as well as potential novel therapeutic targets.
Department
Program
Doctoral Award - Doctoral Foreign Study Award (DFSA)
Recipient
Location
United Kingdom
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
404191
Name
Ng Kevin
Country
United Kingdom
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Endogenous retroelements as novel immune escape mechanisms in human cancers
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Doctoral Foreign Study Award (DFSA)
Keyworddelim
Cancer Genomics; Immunology; Immunotherapy; T Cells
Abstract
Immunotherapy has drastically changed the landscape of cancer treatment. By retargeting the body's own immune system towards a tumour, immunotherapy has proved effective where more traditional therapies have failed. However, tumours have developed sophisticated mechanisms to evade the anti-tumour immune response, thus rendering such immunotherapies ineffective. The advent of next-generation sequencing technologies has highlighted the importance of the non-coding genome in health and disease. A significant proportion of these non-coding genes comprise endogenous retroviruses (ERVs), remnants of ancient viral infections that have since become a part of human DNA. Given their viral origins, these genes have retained their capacity to modulate immune responses. As ERVs and other retroelements are globally deregulated in cancer cells, we propose that they may promote the immune evasive capacity of tumours. Our preliminary analysis of gene expression patterns from 964 cancer patients comprising 31 tumour types has uncovered a novel subset of immune genes that may be regulated by ERVs and other retroelements. My preliminary findings show a novel mechanism by which a retroelement drives expression of alternative soluble form of PD-L1, a molecule that inhibits antitumour immune responses and is thus a key immunotherapeutic target. We propose that this retroelement-derived PD-L1 may affect patient response to immunotherapy, which we will test using in vitro and in vivo models as well as screening patient samples. We aim to uncover diverse mechanisms by which ERVs can contribute to resistance to immunotherapy as well as potential novel therapeutic targets.
Competitiondate
201810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Ng, Kevin
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~